Growth strategy for an emerging biopharmaceutcal company

Inimex Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to the discovery, development and commercialization of new human medicines based on the selective modulation of the innate immune response. Since Inimex’s background is in human drug development, no formal animal health activities have been a part of Inimex operations. This initial analysis shows that Inimex has opportunity in the animal health market. Inimex is in a good place to evaluate a potential revenue-generating growth opportunity that could also develop in-house capabilities and positively increase Inimex’s public profile for future investors. The primary recommendation is the strong encouragement for Inimex to pursue the development of a medicine for companion animal application. For maximum short term revenue, Inimex should bring the medicine into INADA trials then negotiate a deal before entering more resource intensive clinical field trials.